A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

NCT04913285 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult
Non-small Cell Lung Cancer
Melanoma

Interventions

DRUG: KIN-2787
DRUG: KIN-2787 and binimetinib

Sponsor

Pierre Fabre Medicament